Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
- 28 June 2014
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (2) , 149-154
Abstract
Edoxaban, an oral direct factor Xa inhibitor, has been found non-inferior to warfarin for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), with a lower rate of intracranial bleeding. The aim of our investigation was to assess the cost-effectiveness of edoxaban versus warfarin from the perspective of the Italian health-care system. A Markov decision model was used to evaluate lifetime cost and quality-adjusted life expectancy of NVAF patients treated with warfarin or edoxaban. Transition probabilities were obtained from the ENGAGE AF-TIMI 48 trial, cost estimates were based on Italian prices and tariffs, utilities were obtained from the literature. One-way and second-order sensitivity analyses were performed. In the base case, lifetime costs were €18,658 for edoxaban and €14,060 for warfarin. Discounted quality-adjusted survival was 9.022 years for edoxaban and 8.425 years for warfarin, leading to an incremental cost-utility ratio of €7,713 per quality-adjusted life year (QALY) gained. Results were sensitive to time horizon, time in therapeutic range of warfarin and to the relative impact of warfarin versus edoxaban therapy onto quality of life. Probabilistic sensitivity analysis showed edoxaban to be cost-effective versus warfarin in 92.3 % of the simulations at a willingness-to-pay threshold of €25,000 per QALY. In conclusion, edoxaban proved to be a cost-effective alternative to warfarin in patients with moderate-to-high-risk NVAF.Keywords
This publication has 24 references indexed in Scilit:
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness ModelsPLOS ONE, 2013
- The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness studyBMC Neurology, 2012
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Health economics and outcomes research within drug developmentDrug Discovery Today, 2012
- Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in CanadaThrombosis and Haemostasis, 2012
- Cost-effectiveness of Levosimendan in Patients With Acute Heart FailureJournal of Cardiovascular Pharmacology, 2011
- Health economics in drug development: Efficient research to inform healthcare funding decisionsEuropean Journal of Cancer, 2010
- A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic TestingPharmacoEconomics, 2010
- The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the USPharmacoEconomics, 2006
- Risk Factors for Intracerebral Hemorrhage in the General PopulationStroke, 2003